Posted on April 28th, 2009 by
Generic Name: doxorubicin (docks-oh-ROO-bi-sin)
Trade Name: Adriamycin® and Rubex®
For which conditions is this drug approved? Doxorubicin is used for the treatment of several cancers, including bladder, bone, breast, endometrial, gastric, head and neck, kidney, leukemia, liver, lung, lymphomas, mesothelioma, multiple myeloma, neuroblastoma, ovarian, pancreas, prostate, sarcomas, stomach, testis (germ cell), thyroid, uterus, Wilms’ tumor, and Waldenström macroglobulinemia. It is important for patients to remember that physicians have the ability to prescribe medication for conditions other than those for which the drug has been approved by the FDA. Patients who have received a prescription of this drug for a condition other than which it is approved may wish to discuss this issue with their physician.
What is the mechanism of action? Doxorubicin belongs to a group of agents called anthracycline antitumor antibiotics. Doxorubicin produces its anti-cancer effects by binding to DNA and inhibiting the production of proteins necessary for sustaining life of a cell.
How is doxorubicin typically given (administered)? Doxorubicin is administered intravenously (into a vein). If doxorubicin escapes from the vein in which it is being administered, it may cause serious damage to tissue that it comes in contact with. Although patients will be monitored for this, they should tell their healthcare provider immediately if they experience pain, redness, or swelling at the site that doxorubicin is being administered. In addition, patients may experience a reaction to doxorubicin during treatment or immediately following administration. Patients should tell their healthcare providers if they are experiencing difficulty breathing, wheezing, swelling of throat, hives, or swelling of facial features.
How are patients typically monitored? Patients will usually have scheduled meetings with their healthcare provider while they are being treated with doxorubicin. Typically, blood will be drawn to check levels of blood cells and to monitor functions of some organ systems, such as the kidneys or liver. Patients may also undergo physical examinations, scans or other measures to assess side effects and response to therapy.
In addition, patients will have their heart function monitored prior to therapy with doxorubicin and at intervals during therapy, since damage to the heart, although rare, may occur from treatment. The risk of impaired heart function increases with cumulative doxorubicin therapy.
What are the common (occur in 30% or more of patients) side effects of treatment with doxorubicin?
What are the less common (occur in 10% to 29% of patients) side effects of treatment with doxorubicin?
What are the possible late side effects of treatment with doxorubicin? Treatment with doxorubicin may cause damage to the heart, and inhibits its ability to properly pump blood. Patients will be monitored for this side effect; however, they should notify their healthcare provider if they feel chest pain or tightness or extreme fatigue. In addition, patients treated with doxorubicin are at a slightly increased risk of developing a secondary malignancy caused by treatment, such as leukemia. A secondary malignancy is a new and unrelated cancer that occurs in an individual as a result of previous treatment with radiation or chemotherapy. Tumor lysis syndrome may also occur after using doxorubicin. Patients should ask their physician about the possibility of developing a secondary malignancy as a result of their treatment.
This is not a complete list of side effects. Some patients may experience other side effects that are not listed here. Patients may wish to discuss with their physician the other less common side effects of this drug, some of which may be serious.
Some side effects may require medical attention. Other side effects do not require medical attention and may go away during treatment. Patients should check with their physician about any side effects that continue or are bothersome.
What can patients do to help alleviate or prevent discomfort and side effects?
Are there any special precautions patients should be aware of before starting treatment?
When should patients notify their physician?
What is a package insert? A package insert is required by the FDA and contains a summary of the essential scientific information needed for the safe and effective use of the drug for healthcare providers and consumers. A package insert typically includes information regarding specific indications, administration schedules, dosing, side effects, contraindications, results from some clinical trials, chemical structure, pharmacokinetics, and metabolism of the specific drug. By carefully reviewing the package insert, you will get the most complete and current information about how to safely use this drug. If you do not have the package insert for the drug you are using, your pharmacist or physician may be able to provide you with a copy.
Copyright © 2016 CancerConnect Last updated 08/16.
Important Limitations of Use
The information provided above on the drug you have selected is provided for your information only and is not a substitute for consultation with an appropriate medical doctor. We are providing this information solely as a courtesy and, as such, it is in no way a recommendation as to the safety, efficacy, or appropriateness of any particular drug, regimen, dosing schedule for any particular cancer, condition, or patient nor is it in any way to be considered medical advice. Patients should discuss the appropriateness of a particular drug or chemotherapy regimen with their physician.
As with any printed reference, the use of particular drugs, regimens and drug dosages may become out-of-date over time, since new information may have been published and become generally accepted after the latest update to this printed information. Please keep in mind that health care professionals are fully responsible for practicing within current standards, avoiding use of outdated regimens, employing good clinical judgment in selecting drugs and/or regimens, in calculating doses for individual patients, and verifying all dosage calculations.
DISCLAIMER OF WARRANTIES
OMNI HEALTH MEDIA SPECIFICALLY DISCLAIMS AND EXCLUDES ALL EXPRESSED OR IMPLIED WARRANTIES, INCLUDING ANY IMPLIED WARRANTIES AS TO QUALITY, ACCURACY (INCLUDING TYPOGRAPHICAL ERRORS), MERCHANTABILITY, OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE INFORMATION CONTAINED HEREIN. OMNI HEALTH MEDIA DISCLAIMS ALL LIABILITY OR DAMAGES ARISING FROM ANY USE OF THE INFORMATION.
The prescribing physician is solely responsible for making all decisions relating to appropriate patient care including, but not limited to, drugs, regimens, dose, schedule, and any supportive care.
You must be logged-in to the site to post a comment.